37.06
+0.36(+0.98%)
Currency In USD
| Previous Close | 36.7 |
| Open | 37.25 |
| Day High | 37.9 |
| Day Low | 36.6 |
| 52-Week High | 72.29 |
| 52-Week Low | 31.75 |
| Volume | 435,347 |
| Average Volume | 485,903 |
| Market Cap | 2.17B |
| PE | -15.25 |
| EPS | -2.43 |
| Moving Average 50 Days | 47.84 |
| Moving Average 200 Days | 48.82 |
| Change | 0.36 |
If you invested $1000 in Apogee Therapeutics, Inc. (APGE) since IPO date, it would be worth $1,745.64 as of January 19, 2025 at a share price of $37.06. Whereas If you bought $1000 worth of Apogee Therapeutics, Inc. (APGE) shares 1 year ago, it would be worth $1,100.03 as of January 19, 2025 at a share price of $37.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
GlobeNewswire Inc.
Dec 10, 2024 12:00 PM GMT
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus monotherapy Preclinical proof-of-concept achieved f
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
GlobeNewswire Inc.
Dec 02, 2024 11:00 AM GMT
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers Data up to 12 months reinforce APG7
Apogee Therapeutics Announces Agenda for Virtual R&D Day
GlobeNewswire Inc.
Nov 29, 2024 6:00 PM GMT
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inf